MRC1 and neoplasm: The co-injection of 177Lu-labeled anti-α-MMR VHHs and 100-fold unlabelled bivalent anti-α-MMR VHHs most efficiently reduced non-tumoral uptake of VHHs, while high tumor uptake was maintained.